{"type":"trials","record":{"id":28335,"source_id":"clinicaltrials-gov","external_id":"NCT06213038","title":"A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)","brief_summary":"This is a clinical study to evaluate the safety, preliminary efficacy, immunogenicity of SKG0106 in subjects with nAMD.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Youxin Chen","enrollment":12,"countries":["China"],"start_date":"2023-05-05","completion_date":"2025-11-21","last_update_date":"2026-09-11","source_url":"https://clinicaltrials.gov/study/NCT06213038","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Peking Union Medical College Hospital","interventions":["SKG0106"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Characteristics of dose limiting toxicities (DLTs) — 4 weeks","Type, severity, and incidence of ocular and systemic adverse events (AEs) — 48 weeks","Mean change from baseline in best corrected visual acuity (BCVA) at each visit BCVA of the study eye is examined by the…","Mean change from baseline in central subfield thickness (CST) at each visit Spectral domain optical coherence tomograph…","Mean change from baseline in patient-reported outcome (VFQ-25) scale score at each visit Both the total scale and subsc…"],"design_description":"NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","SKG0106"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06213038","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-05-05 to 2025-11-21","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.798Z","intervention":["SKG0106"],"participants":12,"study_design":"NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Characteristics of dose limiting toxicities (DLTs) — 4 weeks","Type, severity, and incidence of ocular and systemic adverse events (AEs) — 48 weeks","Mean change from baseline in best corrected visual acuity (BCVA) at each visit BCVA of the study eye is examined by the…","Mean change from baseline in central subfield thickness (CST) at each visit Spectral domain optical coherence tomograph…","Mean change from baseline in patient-reported outcome (VFQ-25) scale score at each visit Both the total scale and subsc…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28335","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}